ACW Shares Actinogen Medical Limited
BUY ASX · ASXAlzheimer’s trial topline results could materially re-rate the company if efficacy is demonstrated.
Future value: $0.09 (+119.51%) · 6-12 months
Signal breakdown
- ▸Phase 2b/3 XanaMIA topline results expected shortly.
- ▾Below 50-day MA (-19.95%)
- ▸Volume 3.3× average — accumulation
- ▸~120% upside to price target
Is ACW a buy right now?
Trend: ACW is trading below the 50-day average (-16.00%), RSI 38 — neutral momentum, with a 3-month return of +2.44%.
Valuation & quality: Actinogen Medical Limited trades on forward P/E -4.2, price-to-book 7.00; fundamentals show net margin -121.4%, return on equity -77.5%, revenue growth 96.7% year on year.
Analyst consensus: 1 analysts have a mean 12-month price target of A$0.08 (+95.1% vs the last close; range A$0.08 – A$0.08), consensus rating “buy”.
Our screen: BUY (score 2) — Alzheimer’s trial topline results could materially re-rate the company if efficacy is demonstrated.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | -25.00% | +33.30% | +0.00% | +50.00% | -33.30% |
Fundamentals
Analyst price target
Technical signals
About Actinogen Medical Limited
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia.
Sector: Healthcare · Industry: Biotechnology · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.